Andrei Ivanov
University of Southampton
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Andrei Ivanov.
Blood | 2011
Waleed Alduaij; Andrei Ivanov; Jamie Honeychurch; Eleanor J. Cheadle; Sandeep Potluri; Sean H. Lim; Kazuyuki Shimada; Claude H. T. Chan; Alison L. Tutt; Stephen A. Beers; Martin J. Glennie; Mark S. Cragg; Tim Illidge
The anti-CD20 mAb rituximab has substantially improved the clinical outcome of patients with a wide range of B-cell malignancies. However, many patients relapse or fail to respond to rituximab, and thus there is intense investigation into the development of novel anti-CD20 mAbs with improved therapeutic efficacy. Although Fc-FcγR interactions appear to underlie much of the therapeutic success with rituximab, certain type II anti-CD20 mAbs efficiently induce programmed cell death (PCD), whereas rituximab-like type I anti-CD20 mAbs do not. Here, we show that the humanized, glycoengineered anti-CD20 mAb GA101 and derivatives harboring non-glycoengineered Fc regions are type II mAb that trigger nonapoptotic PCD in a range of B-lymphoma cell lines and primary B-cell malignancies. We demonstrate that GA101-induced cell death is dependent on actin reorganization, can be abrogated by inhibitors of actin polymerization, and is independent of BCL-2 overexpression and caspase activation. GA101-induced PCD is executed by lysosomes which disperse their contents into the cytoplasm and surrounding environment. Taken together, these findings reveal that GA101 is able to potently elicit actin-dependent, lysosomal cell death, which may potentially lead to improved clearance of B-cell malignancies in vivo.
Journal of Clinical Investigation | 2009
Andrei Ivanov; Stephen A. Beers; Claire A. Walshe; Jamie Honeychurch; Waleed Alduaij; Kerry L. Cox; Kathleen N. Potter; Stephen M Murray; Claude H. T. Chan; Tetyana Klymenko; Jekaterina Erenpreisa; Martin J. Glennie; Tim Illidge; Mark S. Cragg
mAbs are becoming increasingly utilized in the treatment of lymphoid disorders. Although Fc-FcgammaR interactions are thought to account for much of their therapeutic effect, this does not explain why certain mAb specificities are more potent than others. An additional effector mechanism underlying the action of some mAbs is the direct induction of cell death. Previously, we demonstrated that certain CD20-specific mAbs (which we termed type II mAbs) evoke a nonapoptotic mode of cell death that appears to be linked with the induction of homotypic adhesion. Here, we reveal that peripheral relocalization of actin is critical for the adhesion and cell death induced by both the type II CD20-specific mAb tositumomab and an HLA-DR-specific mAb in both human lymphoma cell lines and primary chronic lymphocytic leukemia cells. The cell death elicited was rapid, nonapoptotic, nonautophagic, and dependent on the integrity of plasma membrane cholesterol and activation of the V-type ATPase. This cytoplasmic cell death involved lysosomes, which swelled and then dispersed their contents, including cathepsin B, into the cytoplasm and surrounding environment. The resulting loss of plasma membrane integrity occurred independently of caspases and was not controlled by Bcl-2. These experiments provide what we believe to be new insights into the mechanisms by which 2 clinically relevant mAbs elicit cell death and show that this homotypic adhesion-related cell death occurs through a lysosome-dependent pathway.
Blood | 2012
Jamie Honeychurch; Waleed Alduaij; Mahsa Azizyan; Eleanor J. Cheadle; Helene Pelicano; Andrei Ivanov; Peng Huang; Mark S. Cragg; Tim Illidge
Monoclonal antibodies (mAbs) have revolutionized the treatment of B-cell malignancies. Although Fc-dependent mechanisms of mAb-mediated tumor clearance have been extensively studied, the ability of mAbs to directly evoke programmed cell death (PCD) in the target cell and the underlying mechanisms involved remain under-investigated. We recently demonstrated that certain mAbs (type II anti-CD20 and anti-HLA DR mAbs) potently evoked PCD through an actin-dependent, lysosome-mediated process. Here, we reveal that the induction of PCD by these mAbs, including the type II anti-CD20 mAb GA101 (obinutuzumab), directly correlates with their ability to produce reactive oxygen species (ROS) in human B-lymphoma cell lines and primary B-cell chronic lymphocytic leukemia cells. ROS scavengers abrogated mAb-induced PCD indicating that ROS are required for the execution of cell death. ROS were generated downstream of mAb-induced actin cytoskeletal reorganization and lysosome membrane permeabilization. ROS production was independent of mitochondria and unaffected by BCL-2 overexpression. Instead, ROS generation was mediated by nicotinamide adenine dinucleotide phosphate (NADPH) oxidase. These findings provide further insights into a previously unrecognized role for NADPH oxidase-derived ROS in mediating nonapoptotic PCD evoked by mAbs in B-cell malignancies. This newly characterized cell death pathway may potentially be exploited to eliminate malignant cells, which are refractory to conventional chemotherapy and immunotherapy.
Journal of Cell Science | 2003
Andrei Ivanov; Mark S. Cragg; Jekaterina Erenpreisa; Dzintars Emzinsh; Henny Lukman; Timothy M. Illidge
p53 mutant tumour cells respond to genotoxic insults by bypassing G1 arrest and halting in G2. Following release from G2 arrest they undergo mitotic catastrophe, whereby mitotic cycling is suppressed, delayed apoptosis begins and endopolyploid cells are produced. The ability of these endopolyploid cells to participate in the restitution process is controversial. To facilitate recovery, these endopolyploid cells must repair the extensive DNA damage induced. DNA damage and its resolution were studied by observing the kinetics of γ-H2AX foci formation and by comet assay analysis. Subsequently, the kinetics and distribution of Rad51 foci were studied as a measure of homologous recombination. Here we present evidence of the resolution of DNA damage in endopolyploid cells through a decrease of tail moment by comet assay and in the number of cells expressing γ-H2AX foci. Rad51 foci expression reached a maximum in endopolyploid cells on days 5-6 after irradiation, when delayed apoptosis was maximal, indicating that cells were being selected for survival at this time. Furthermore, the proportion of Annexin-V-positive polyploid cells decreased as they continued ongoing rounds of DNA replication, suggesting endoreduplication is involved in selecting cells resistant to apoptosis. Our findings suggest that after severe genotoxic insult endopolyploid cells have a transient survival advantage that may contribute to radioresistance of tumours that undergo mitotic catastrophe.
Cell Biology International | 2005
Jekaterina Erenpreisa; Martins Kalejs; Fiorenza Ianzini; Elizabeth A. Kosmacek; Mike Mackey; Dzintars Emzinsh; Mark S. Cragg; Andrei Ivanov; Timothy M. Illidge
Following irradiation p53‐function‐deficient tumour cells undergo mitotic catastrophe and form endopolyploid cells. A small proportion of these segregates nuclei, and give rise to viable descendants. Here we studied this process in five tumour cell lines. After mitotic failure, tumour cells enter the endocycle and form mono‐nucleated or multi‐nucleated giant cells (MOGC and MNGC). MNGC arise from arrested anaphases, MOGC, from arrested metaphases. In both cases the individual genomes establish a radial pattern by links to a single microtubule organizing centre. Segregation of genomes is also ordered. MNGC present features of mitosis being resumed from late anaphase. In MOGC the sub‐nuclei retain arrangement of stacked metaphase plates and are separated by folds of the nuclear envelope. Mitosis then resumes in sub‐nuclei directly from metaphase. The data presented indicate that endopolyploid tumour cells preserve the integrity of individual genomes and can potentially re‐initiate mitosis from the point at which it was interrupted.
Experimental Cell Research | 2010
Kristine Salmina; Eriks Jankevics; Anda Huna; Dmitry Perminov; Ilze Radovica; Tetyana Klymenko; Andrei Ivanov; Elina Jascenko; Harry Scherthan; Mark S. Cragg; Jekaterina Erenpreisa
We have previously documented that transient polyploidy is a potential cell survival strategy underlying the clonogenic re-growth of tumour cells after genotoxic treatment. In an attempt to better define this mechanism, we recently documented the key role of meiotic genes in regulating the DNA repair and return of the endopolyploid tumour cells (ETC) to diploidy through reduction divisions after irradiation. Here, we studied the role of the pluripotency and self-renewal stem cell genes NANOG, OCT4 and SOX2 in this polyploidy-dependent survival mechanism. In irradiation-resistant p53-mutated lymphoma cell-lines (Namalwa and WI-L2-NS) but not sensitive p53 wild-type counterparts (TK6), low background expression of OCT4 and NANOG was up-regulated by ionising radiation with protein accumulation evident in ETC as detected by OCT4/DNA flow cytometry and immunofluorescence (IF). IF analysis also showed that the ETC generate PML bodies that appear to concentrate OCT4, NANOG and SOX2 proteins, which extend into complex nuclear networks. These polyploid tumour cells resist apoptosis, overcome cellular senescence and undergo bi- and multi-polar divisions transmitting the up-regulated OCT4, NANOG and SOX2 self-renewal cassette to their descendents. Altogether, our observations indicate that irradiation-induced ETC up-regulate key components of germ-line cells, which potentially facilitate survival and propagation of the tumour cell population.
Cell Biology International | 2008
Jekaterina Erenpreisa; Andrei Ivanov; Sally P. Wheatley; Elizabeth A. Kosmacek; Fiorenza Ianzini; Alim P. Anisimov; Michael A. Mackey; Paul J. Davis; Grigorijs Plakhins; Tim Illidge
Recent findings including computerised live imaging suggest that polyploidy cells transiently emerging after severe genotoxic stress (and named ‘endopolyploid cells’) may have a role in tumour regrowth after anti‐cancer treatment. Until now, mostly the factors enabling metaphase were studied in them. Here we investigate the mitotic activities and the role of Aurora‐B, in view of potential depolyploidisation of these cells, because Aurora‐B kinase is responsible for coordination and completion of mitosis. We observed that endopolyploid giant cells are formed via different means in irradiated p53 tumours, by: (1) division/fusion of daughter cells creating early multi‐nucleated cells; (2) asynchronous division/fusion of sub‐nuclei of these multi‐nucleated cells; (3) a series of polyploidising mitoses reverting replicative interphase from aborted metaphase and forming giant cells with a single nucleus; (4) micronucleation of arrested metaphases enclosing genome fragments; or (5) incomplete division in the multi‐polar mitoses forming late multi‐nucleated giant cells. We also observed that these activities can release para‐diploid cells, although infrequently. While apoptosis typically occurs after a substantial delay in these cells, we also found that ∼2% of the endopolyploid cells evade apoptosis and senescence arrest and continue some form of mitotic activity. We describe here that catalytically active Aurora‐B kinase is expressed in the nuclei of many endopolyploid cells in interphase, as well as being present at the centromeres, mitotic spindle and cleavage furrow during their attempted mitotes. The totally micronucleated giant cells (containing sub‐genomic fragments in multiple micronuclei) represented only the minor fraction which failed to undergo mitosis, and Aurora‐B was absent from it. These observations suggest that most endopolyploid tumour cells are not reproductively inert and that Aurora‐B may contribute to the establishment of resistant tumours post‐irradiation.
Clinical Cancer Research | 2008
Andrei Ivanov; Sergei Krysov; Mark S. Cragg; Tim Illidge
Purpose: The use of targeted radiation therapy (RT) in conjunction with anti-CD20 monoclonal antibodies (mAb) delivers high clinical response rates in B-cell lymphomas as part of radioimmunotherapy. The mechanisms underlying these impressive responses, particularly in patients whose lymphomas have become refractory to chemotherapy, are poorly understood. Experimental Design: In this study, we have investigated the signaling pathways and mode of cell death induced in B-cell lymphoma cells after the combination of RT and either type I (rituximab) or type II (tositumomab/B1) anti-CD20 mAb. Results: Increased tumor cell death was observed when RT was combined with tositumomab, but not rituximab. This additive cell death was found to be mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK)–dependent and could be reversed with mitogen-activated protein/extracellular signal-regulated kinase kinase (MEK) inhibitors, as well as small interfering RNA targeting MEK1/2. Furthermore, we found that this increased death was associated with ERK1/2 nuclear accumulation after tositumomab treatment, which was enhanced in combination with RT. Importantly, although Bcl-2 overexpression resulted in resistance to RT-induced apoptosis, it had no effect on the tumor cell death induced by tositumomab plus RT, indicating a nonapoptotic form of cell death. Conclusions: These findings indicate that RT and type II anti-CD20 mAb combine to stimulate a prodeath function of the MEK-ERK1/2 pathway, which is able to overcome apoptotic resistance potentially explaining the efficacy of this modality in treating patients with chemoresistant disease.
Archive | 2008
Andrei Ivanov; M. Ivanova; Jekaterina Erenpreisa; S. V. Gloushen; Talivaldis Freivalds; Mark S. Cragg
Homologous recombination of DNA double strand breaks was previously found to be protective against apoptosis in tumor cells lacking p53 function. Here, we studied the spatial and temporal relationship between the two processes in a pair of lymphoblastoid cell lines with wild-type or mutant p53 status. Clonogenic assays revealed that p53 mutant WI-L2-NS cells were ≈ ten-fold more resistant to X-ray damage than p53 wild type TK6 cells and displayed 2–3 times lower levels of apoptosis 24 h after irradiation. The kinetics of DNA damage and repair after irradiation (5 Gy) were assessed by immunofluorescent staining for g-H2AX and Rad51, and DNA stained with DAPI. Using image analysis in the three (red/green/blue) fluorescence channels we found that repair foci were more prevalent in the p53 mutant radioresistant WI-L2-NS cells at many time points: 2.2 versus 1 per nucleus at 5 min, 3.2 versus 1.6 at 6 h, and 6.1 versus 3.6 at 72 h post-irradiation although the number of repair foci were equal at 24 h (8.8). Furthermore, the average size of foci in TK6 cells was smaller at all times post-irradiation (p<0.001). In contrast to the functional repair foci which were characterised by the co-localisation and high concentration of g-H2AX and Rad51, in pre-apoptotic cell nuclei, foci with greater quantities of g-H2AX relative to Rad51 were prevalent. The g-H2AX-predominant foci colocalized with little or no Rad51 and fused in a pattern typical of apoptotic chromatin. This pattern was seen more often in TK6 cells, where at 6 h the sum area occupied by g-H2AX was seven-fold higher than that of the Rad51 label. In contrast, WI-L2-NS cells displayed approximately equal areas of both components. These data suggest that formation of stable functional repair foci topologically protects the chromatin from relaxation and initiation of apoptotic fragmentation.
Blood | 2011
Jamie Honeychurch; Waleed Alduaij; Eleanor J. Cheadle; Mahsa Azizyan; Helene Pelicano; Peng Huang; Andrei Ivanov; Mark S. Cragg; Tim Illidge